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Chronic kidney disease (CKD) leads to an 18-fold increase
in cardiovascular complications not fully explained by
traditional risk factors. Levels of renalase, a recently
discovered oxidase that metabolizes catecholamines, are
decreased in CKD. Here we show that renalase deficiency
in a mouse knockout model causes increased plasma
catecholamine levels and hypertension. Plasma blood urea
nitrogen, creatinine, and aldosterone were unaffected.
However, knockout mice had normal systolic function and
mild ventricular hypertrophy but tolerated cardiac ischemia
poorly and developed myocardial necrosis threefold more
severe than that found in wild-type mice. Treatment with
recombinant renalase completely rescued the cardiac
phenotype. To gain insight into the mechanisms mediating
this cardioprotective effect, we tested if gene deletion
affected nitrate and glutathione metabolism, but found no
differences between hearts of knockout and wild-type mice.
The ratio of oxidized (NAD) to reduced (NADH) nicotinamide
adenine dinucleotide in cardiac tissue, however, was
significantly decreased in the hearts of renalase knockout
mice, as was plasma NADH oxidase activity. In vitro
studies confirmed that renalase metabolizes NADH and
catecholamines. Thus, renalase plays an important role
in cardiovascular pathology and its replacement may
reduce cardiac complications in renalase-deficient states
such as CKD.
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Patients with chronic kidney disease (CKD) and end-stage renal
disease develop coronary disease at a significantly higher rate
than the general population.1–4 Although traditional risk factors
such as hypertension and hyperlipidemia are prevalent in CKD
patients, they do not appear to fully account for the increased
cardiac disease burden. It has been hypothesized that additional
risk factors, including heightened sympathetic tone,5–8 oxidative
stress,9 and arterial calcification, also contribute to the develop-
ment of coronary artery disease in patients with CKD. For
instance, plasma norepinephrine (NE) concentration predicts
survival and incident cardiovascular events in patients with end-
stage renal disease.10 Sympathetic nerve activity, a proxy for
sympathetic tone, and plasma catecholamine concentrations are
elevated in patients with CKD stage 3 and above. The increase in
plasma catecholamine concentrations appears to be because of an
increase in their production, with spillover into the circulation, in
addition to a reduction in their clearance.
We recently identified renalase, a novel flavin adenine
dinucleotide (FAD)-dependent oxidase that participates in
catecholamine metabolism. It is expressed in kidney, heart,
and skeletal muscle, and secreted into the blood by the
kidney.11 Plasma renalase levels are decreased in patients with
CKD and end-stage renal disease.11,12 Plasma and kidney
renalase levels are decreased in animals subjected to subtotal
nephrectomy (5/6 Nx), thus providing a plausible explana-
tion for the decreased catecholamine clearance observed in
CKD.13,14 A significant reduction in cardiac renalase levels
was observed in the 5/6 Nx rat model.13,14 This is particularly
significant as the abnormal regulation of catecholamine
metabolism contributes to the pathogenesis of left ventricular
hypertrophy, ventricular arrhythmia, myocardial ischemia,
and myocardial necrosis. We have further shown that renalase
circulates as a proenzyme that lacks enzymatic activity under
baseline conditions, and that is rapidly activated by elevated
plasma catecholamines.13 Additionally, two single-nucleotide
polymorphisms in the renalase gene (rs2576178 GG genotype
and rs2296545 CC) are associated with essential hyperten-
sion.15 Interestingly, rs2296545 CC results in a conservative
amino-acid change (glutamic to aspartic acid at amino acid
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37 (E37D)) within the FAD-binding domain, and may affect
the affinity of the binding site for FAD.
In this work, we used a knockout (KO) mouse model to
examine the link between renalase deficiency, hypertension,
and cardiovascular disease, and to gain insight into the
mechanisms mediating renalase’s cardioprotective effect.
RESULTS
Hypertension in renalase-deficient mice
Renalase plasma and tissue levels are decreased in animal
models of CKD.13,14 To test the hypothesis that renalase
deficiency alone aggravates cardiac ischemic injury, we
generated a renalase KO mouse by disrupting the renalase
locus using homologous recombination. The targeting
construct, shown in Figure 1a, deletes the promoter region
and a large part of the coding region. Gene disruption was
confirmed by genomic Southern blot (Figure 1b), PCR
(Figure 1c), and western blot (Figure 1d). Renal function,
assessed by blood urea nitrogen, serum creatinine, and
urinary protein excretion, was unaffected by renalase
deletion. Several noteworthy phenotypic characteristics are
shown in Table 1. Blood pressure (BP) and heart rate were
higher in anesthetized KO mice, and plasma aldosterone
concentrations were not significantly different between wild-
type (WT) and KO mice. As depicted in Figure 2, KO mice
had higher plasma dopamine, epinephrine, and NE than WT
mice. Adrenergic sensitivity was tested using TOCRIS
A-61603 hydrobromide (St Louis, MO), a highly specific
a-adrenergic receptor 1A/C agonist (aAR1A/C). Infusion of
TOCRIS A-61603 at 0.2mg/kg/min for 10min increased BP
significantly more in renalase KO mice than in WT (Figure 3a).
Ambulatory, telemetric BP measurements in conscious
mice confirmed systolic and diastolic hypertension in the
renalase KO, with a relatively greater elevation in diastolic
pressure. Both KO and WT mice exhibit normal diurnal
variations with peak pressure at B2300 hours (Figure 3b).
Systolic and diastolic pressures were significantly elevated in
KO mice both during activity (Figure 3c) and at rest (Figure 3d).
During the active period, renalase KO mice had a
significantly higher heart rate than WT controls (627±9 vs
582±10 beats/min, n¼ 7, Po0.004). Renalase KO mice had
a normal left ejection fraction (in %, WT: 49.86±5.15 vs KO:
53.24±4.33, n¼ 7), and left ventricular hypertrophy as
evidenced by increased left ventricular posterior wall
thickness (in mm, WT: 0.79±0.11 vs KO: 0.94±0.09,
n¼ 7, Po0.02), and smaller left ventricular diameter (in
mm, WT: 4.50±0.07 vs KO: 4.23±0.09, n¼ 7, Po0.05), as
assessed by transthoracic echocardiography. The left ventri-
cular mass of KO mice was not significantly different from
that of WT (in mg, WT: 167.06±15.45 vs KO: 170.89±8.09,
n¼ 7, P¼ 0.83).
Renalase deficiency aggravates ischemic cardiac damage
To test if renalase deficiency modulates the response to
cardiac ischemia, isolated perfused hearts were exposed to
15min of global ischemia, followed by reperfusion for
90min. Myocardial damage was assessed by triphenyltetra-
zolium staining of the heart. Viable tissue stains red, whereas
damaged tissue fails to pick up the stain and appears pale.
The degree of myocardial necrosis was qualitatively greater in
renalase KO hearts (Figure 4a). Infarct size was quantified by
computer-assisted planimetry (ImageJ 1.34s, National Insti-
tute of Health (NIH) Washington, DC), and as shown in
Figure 4b, myocardial damage was threefold greater in KO
mice. The cardioprotective effect of recombinant renalase was
assessed by subjecting isolated KO mouse heart to global
ischemia for 15min, and then reperfusing for 90min with
buffer containing either renalase or glutathione synthase.
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Figure 1 |Generation of renalase knockout (KO) mouse.
(a) Targeting vector. E1–E6: exons 1–6; probe a3: 30 end probe
external to deleted region labels 12.3 and 8.3 kb Xba1 fragments
in wild-type (WT) and KO, respectively. (b) Embryonic stem (ES)
cell screen. Genomic Southern of ES cells using probe a3; *positive
ES clone. (c) Mouse genotyping by PCR. The 499 bp band: WT
allele; 292 bp band: KO allele. (d) Western blot of mouse tissue
from WT and KO. The arrow indicates band of the expected size
(37 kd) for renalase protein; 52.5 kd band in heart and kidney is
nonspecific.
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As shown in Figure 4c and d, compared with glutathione
S-transferase, reperfusion with recombinant renalase was
associated with a dramatic reduction in ischemic myocardial
damage in renalase KO hearts.
Mechanisms of cardioprotection by renalase
As cardiac catecholamines, renalase substrates, increase by
B100-fold during cardiac ischemia in vivo,16 it is likely that
renalase’s cardioprotective effect is mediated in part by its
ability to metabolize excess NE and epinephrine. In support
of this notion is the finding that in the isolated perfused heart
model, NE administration caused a greater increase in the
rate-pressure product in KO hearts compared with WT hearts
(Figure 4e).
To search for additional mechanisms, we tested if renalase
deletion altered the metabolism of non-amine compounds
known to affect endothelial function and myocardial
metabolism. Nitrate and nitrite concentrations in tissue and
plasma did not differ significantly between WT and KO mice,
suggesting that renalase deficiency does not affect nitrate
metabolism. Similar levels of oxidized and reduced glu-
tathione levels (plasma, kidney, heart, and liver) were
measured in WT and renalase KO.
In silico analysis of renalase’s secondary structure indicated
that in addition to an FAD-binding motif, it also contained a
putative NAD/NADH-binding site, which suggested that it
might use NADH to reduce oxidized flavin, and therefore,
function as a NADH oxidase.
We next tested whether renalase deficiency affected the
cellular NAD/NADH ratio, and found a significant reduction
in the ratio of oxidized to reduced nicotinamide adenine
dinucleotide (NAD/NADH) in the cardiac tissue (Figure 5a).
Plasma and tissue NADH oxidase activities were measured
and found to be markedly decreased in renalase KO animals,
supporting the hypothesis that renalase possesses NADH
oxidase activity (Figure 5b). Recombinant renalase was tested
in vitro, and was also found to have significant NADH
oxidase activity in the absence of catecholamine substrates.
Kinetic parameters, estimated by fitting initial velocity vs
substrate concentration values to the Michaelis–Menten
equation using nonlinear regression, were as follows: Km
(NADH)¼ 15.23±2.16 mM and Vmax¼ 15.27±0.84 nmol/
min per mg protein at 37 1C (Figure 5c).
DISCUSSION
Disruption of the renalase gene in mice causes hypertension
in the absence of any measurable change in renal function.
Continuous hemodynamic monitoring by telemetry revealed
elevated BP in the KO animals during activity and at rest. The
marked increase in diastolic pressure suggests heightened
peripheral vasoconstriction in the renalase KO, as would be
expected if renalase had a significant role in catecholamine
metabolism. Under basal conditions, plasma catecholamines
were significantly elevated in the renalase KO. Administration
of a specific aAR1A/C agonist at a dose that minimally
affected BP in WT animals caused a marked increased blood
pressure in KO animals, indicating increased sensitivity to
adrenergic stimulation. Furthermore, exogenous NE was
associated with a greater hemodynamic effect in the KO
heart, suggesting that renalase is likely to participate in the
acute response to catecholamine release. This is in line with
previous results indicating that an acute increase in plasma
catecholamine concentrations rapidly activates circulating
Table 1 | Comparison of renalase KO and WT mice
WT KO n P-value
Weight at 3 months (g) 30.8±1.5 26.5±1.2 20 o0.001
Activity index (AU) 4.54 6.01 4 o0.05
Anesthetized BP (mmHg)
Systolic 92.9±3.4 103.2±4.6 4 o0.04
Diastolic 61.7±2.1 72.6±2.0 o0.02
Mean 74.5±2.3 85.2±2.8 o0.02
Anesthetized heart rate (b.p.m.) 406.7±38.1 509.3±45.5 4 o0.05
Plasma aldosterone (pg/ml) 797.6±82.9 796.6±83.9 30 0.99
Plasma electrolytes (mEq/l)
Sodium 144.9±1.1 147.4±0.9 10 0.06
Potassium 5.1±0.1 4.7±0.1 o0.001
Chloride 114.0±0.5 117.0±0.5 o0.001
Blood glucose (mg/dl) 238.6±1.3 235.1±0.9 10 0.43
Blood urea nitrogen (mg/dl) 17.2±0.2 16.9±0.3 10 0.26
Serum creatinine (mg/dl) 0.136±0.012 0.130±0.006 10 0.67
Urine protein/creatinine ratio 0.49±0.21 0.45±0.17 10 0.76
Reduced glutathione (nmol/mg protein)
Plasma 0.292±0.011 0.264±0.014 6 0.44
Heart 2.94±0.31 3.12±0.29 0.59
Liver 8.77±1.13 8.66±1.26 0.63
Kidney 5.34±0.41 5.34±0.41 0.96
Nitrate+nitrite (mM)
Plasma 3.12±0.41 3.29±0.45 6 0.37
Heart 18.32±2.13 19.17±2.37 0.33
Liver 6.11±1.39 5.22±0.94 0.42
Kidney 8.59±1.67 7.91±1.28 0.52
Abbreviations: AU, arbitrary units; BP, blood pressure; KO, knockout; WT, wild type.
Higher activity index indicates greater levels of activity.
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Figure 2 | Elevated plasma catecholamines in renalase
knockout (KO). Plasma levels of dopamine, norepinephrine, and
epinephrine in wild-type (WT, n¼ 9) and renalase knockout mice
(n¼ 11) at 7 weeks of age. *Po0.05; **Po0.01.
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renalase and stimulates the secretion of the preformed
enzyme,13 and suggest that the increase in BP pressure
observed in the KO mice is most likely of neurogenic origin.
Two single-nucleotide polymorphisms (rs2576178 GG
genotype and rs2296545 CC) within the renalase gene are
reported to be associated with essential hypertension.15
Single-nucleotide polymorphism rs2296545 CC results in a
conserved amino-acid change at amino acid 37 (glutamic to
aspartic acid) within the FAD-binding domain (E37D). In
monoamine oxidase-B, the FAD-binding domain consists of a
b1 sheet-a1 helix–b2 sheet, beginning with a highly conserved
GxGxxG motif, and ending with glutamic acid at position 34
(E34).17,18 Site-directed mutagenesis of monoamine oxidase-B
at position 34 revealed that a negative charge was absolutely
required for function as E34A was nonfunctional and,
surprisingly, although the negative charge was conserved in
the E34D mutant, it was 93% less active that WTmonoamine
oxidase-B.18 These data suggest that single-nucleotide poly-
morphism rs2296545 CC (E37D) may have profound effects
on the enzymatic activity of renalase.
Renalase KO mice tolerate cardiac ischemia poorly, and
when exposed to an ischemic insult develop myocardial
necrosis that is threefold more severe than that seen in WT
littermates. This difference cannot be explained by the mild
hypertension and left ventricular hypertrophy that was
observed in the renalase KO mice. Catecholamine levels
increase markedly in the ischemic myocardium, and a 600-
fold rise in norepinephrine levels has been documented by
microdialysis in myocardial interstitial fluid of the ischemic
pig heart.16 Catecholamine release induced by ischemia does
not depend on continuous cardiac innervation, and has been
documented in the isolated perfused heart preparation.19
In these studies, NE levels, measured from the coronary
venous effluent, rose by 20-fold following 15min of global
ischemia. This corresponds to an increase in extracellular
concentration of NE from 20 nM to 1 mM, a level that is well
within the range known to cause myocardial necrosis.20 It is,
therefore, likely that the protective effect of exogenous
renalase is due in part to its ability to metabolize
catecholamines. Increased catecholamine levels are believed
to aggravate cellular injury and predispose to malignant
ventricular arrhythmias. Under basal conditions, the neuro-
nal NE carrier (Uptake 1) transports NE into cells, and it
appears to work in reverse during ischemia. Circulating
renalase is known to be activated by catecholamine surges
and could have a key role in limiting the accumulation of NE
in myocardial interstitial fluid during ischemia, and further
speed up its removal upon reperfusion. Renalase deficiency
would be expected to impair NE disposal, which may explain
the marked increased in ischemic cardiac injury observed in
the renalase KO heart, and the cardioprotective effect of
recombinant renalase.
A large proportion of the NE that accumulates in the
myocardial interstitial fluid during ischemia is reported to
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Figure 3 | Elevated blood pressure in renalase KO. (a) Increased sensitivity of a-adrenergic receptor 1A/C (aAR1A/C) in renalase KO.
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come from cardiac nerves.16 As our studies employed the
isolated perfused heart model, which is denervated and has
significantly lower catecholamine levels than the intact
heart,21 it is possible that catecholamine-independent mecha-
nisms also have a role in mediating renalase’s cardioprotec-
tive action. We found no evidence that renalase deficiency
affected either nitrate or glutathione metabolism. Plasma and
tissue nitrate and nitrite did not differ between KO and WT
mice, suggesting that nitric oxide deficiency was an unlikely
explanation of the KO’s cardiovascular phenotype. Similarly,
there were no changes in oxidized and reduced glutathione,
which indicates that oxidative stress does not appear to be a
major factor. However, renalase deficiency was associated
with a significant decrease in the cellular NAD/NADH ratio.
NAD is critically important in energy metabolism and
electron transfer reactions. It modulates the activity of the
NAD-dependent type III deacetylase surtuin-1 (SIRT1),
which participates in metabolic homeostasis and cell survival
pathways.22 Elevated NAD levels enhance SIRT1 activity,
resulting in the deacetylation and modulation of the activity
of downstream targets such as transcription factors (FOXO1
and FOXO3a) and the peroxisome proliferator-activated
receptor-c coactivator 1a. A decrease in the NAD/NADH ratio
would be expected to aggravate myocardial injury during
ischemia, and impair cardiac contractility during reperfusion.
We also found that plasma NADH oxidase activity was
significantly lower in renalase KO, suggesting that plasma
renalase contributes to the regulation of extracellular NAD
(NADex) level. Although NAD’s role as a coenzyme is well
described, its involvement in cell signaling pathways has only
recently been documented. NADex reportedly serves as a
substrate for nucleotide-metabolizing enzymes, and as ligand
for extra- and intra-cellular receptors and ion channels.23
NADex regulates intracellular calcium signaling by inter-
acting with specific cell surface receptors, such as the human
P2Y11 purinergic receptor.24,25 Although plasma NAD levels
are difficult to measure accurately, they reportedly range
between 0.1 and 4 mM. The conversion of NADH to NAD by
plasma NADH oxidases is among the factors believed to
contribute to the pool of NADex. The others include cell
lysis, dephosphorylation of Cx43 hemichannels, and incre-
ased NAD release from cells.26 Our data suggest that renalase
may function as a plasma NADH oxidase, and it regulates
NADex.
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Figure 4 |Cardioprotective effect of renalase. (a) Increased ischemic myocardial damage in renalase KO. Triphenyltetrazolium (TTZ) stains
of WT and KO hearts exposed to 15min of global ischemia followed by 90min of reperfusion; red stain indicates viable myocardium.
KO, renalase knockout; WT, wild-type littermates. (b) Ischemic cardiac necrosis in WT and KO quantified using ImageJ. (c) Cardioprotective
effect of recombinant renalase. TTZ stains of KO heart exposed to 15min of global ischemia followed by 90min of reperfusion with or
without recombinant renalase; red stain indicates viable myocardium. (d) Recombinant renalase’s cardioprotective effect quantified using
ImageJ. *Po0.002, n¼ 4. (e) Hemodynamic effect of norepinephrine in KO. *Po0.04, n¼ 4.
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Recombinant renalase metabolizes NADH in the absence
of catecholamines, and its Vmax compares favorably with
that of bacterial27 and also mammalian NADH oxidases such
as apoptosis-inducing factor.28 Unlike apoptosis-inducing
factor, it is specific for NADH and does not metabolize
NADPH. Sera from patients suffering from cancer contain a
capsaicin-sensitive NADH oxidase. The activity is reported to
track with a protease-resistant 33.5 kd protein.29 It is unclear
if this protein also metabolizes NADPH, and its relationship
to renalase is unknown at present.
In summary, renalase deficiency alone, in the absence
of measurable changes in renal function, is associated
with increased BP and susceptibility to ischemic myocardial
damage. Renalase’s cardioprotective effect appears to be
mediated not only by its ability to metabolize catechola-
mines, but also by its effect of extracellular NAD and cellular
redox metabolism (Figure 5d). Renalase levels in the plasma,
kidney, and heart are decreased in CKD and end-stage
renal disease. Taken together, these data support the notion
that renalase has an important role in the regulation of BP
and prevention of cardiac ischemic damage. We speculate
that renalase deficiency increases the risk of cardiac
arrhythmias and ischemic injury in patients with CKD, and
that renalase replacement therapy may improve cardiovas-
cular outcome in CKD.
MATERIALS AND METHODS
Generation of renalase KO mice
The animal studies were carried out according to the protocols
approved by the institutional animal care and use committee of VA
Connecticut Health Care System. The targeting vector was designed
to delete a 10.048-kb region from the renalase gene, encompassing
exons 1–4 and 4.465-kb upstream of the 50 untranslated region
(Figure 1a). To that end, we amplified 50 and 30 sequences (1.7 and
2.2 kb, respectively) flanking the region to be deleted by PCR from
genomic DNA isolated from a 129Sv/J mouse, using the following
primers: (F-50-GAACGCGTCGACTTGTTTGAGTTCATAGTGGGG
GAG-30, R-50-GAACGCGTCGACTACTGCTGCTGCTGTTCTTGG
TGG-30); (F-50-AAGGAAAAAAGCGGCCGCTGTAGTCCTGGGTT
GTGGGTTC-30, R-50-AAGGAAAAAAGCGGCCGCTGGGAAGGTG
AAATGTCTCCG-30). The amplified 1.7-kb 50 DNA sequence was
ligated into the Sal1 site of pEasy Flox downstream to the neomycin
gene (Neo), whereas the 2.2-kb 30 fragment was cloned into the Not1
site, upstream to the Neo gene. The targeting vector was linearized
using Cla1, and 25mg DNA was electroporated into 107 W9.5
embryonic stem cells. Cells were plated onto mitomycin C-treated
embryonic fibroblasts and drug selection begun 24 h later.
Embryonic stem cells were screened with probe a3 (849 bp PCR
product: forward- 50-CCTGACCCTTCTTCTGAACACACC-30, reverse-
50-TGACTGGCTTTTCTCTTTGAGTGG-30), which detects different
Xba1 fragment sizes in WT (12.3 kb) and recombinant (8.3 kb)
renalase. Embryonic stem cells that underwent homologous
recombination were selected and injected into C5BL/6 blastocysts,
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and chimeric males were bred to C5BL/6 females. All mice were
housed in specific pathogen-free conditions in accordance with the
institutional animal care and use guidelines. WT and renalase KO
mice were identified by PCR of tail genomic DNA (WT 499 bp
product, F, 50-AAATCCCCAGTTACTTATGGCTCC-30, R, 50-GAGA
CAGTGACAGAGAGAAACCAGC-30; renalase KO 292 bp product, F,
50-AGGCTATTCGGCTATGACTGGG-30, R, 50-TGGATACTTTCTC
GGCAGGAGC-30). Gene deletion was confirmed by genomic
Southern blot, reverse transcriptase-PCR of kidney tissue, and by
western blotting of heart and kidney tissue. Renalase KO mice and
control littermates used in these studies were F10–F12 offsprings
obtained from B6/129 intercrosses.
Anesthetized BP measurements
BP were measured as previously described.11,30 In brief, mice
(20–40 g) were anesthetized with inactin (100mg/kg), and a catheter
(PE-50, Warner Instruments, Hamden, CT) was placed in the
trachea for airway protection and in the left jugular vein (PE-10,
Warner Instruments, Hamden, CT) for intravenous infusion of a
maintenance fluid solution consisting of normal saline with 2.25%
bovine albumin, at a rate of 12 ml per g body weight per hour. Core
temperature was monitored using a rectal thermometer and body
temperature was maintained at 37 1C using a heating pad. Arterial
pressure and pulse were continuously monitored through a catheter
inserted in the right carotid artery and connected to a pressure
transducer (ADInstruments, Colorado Springs, CO). Hemodynamic
recordings were digitized, stored, and analyzed using a PowerLab/
8SP data acquisition system (ADIntruments). The mice were
allowed 1 h to recover after completion of the surgical procedure,
and BP and pulse were continuously recorded during the sub-
sequent 30min.
Ambulatory BP measurements
Ambulatory BP in mice was measured via telemetry using BP
transducers (Data Sciences International, St Paul, MN, model
TA11PA-C10) implanted into the carotid artery using sterile
technique. The catheter of the transducer was inserted into the
carotid artery and secured in place with silk suture. The body of the
transducer was introduced into a subcutaneous pocket formed on
the right lateral flank. Mice were allowed to recover for 7 days after
surgery to regain their normal circadian rhythms before experiments
were initiated. The animals were fed a standard (24%) protein diet
(Purina, St Louis, MO) and synchronized to a 12/12 h light (0600 to
1800 hours) and dark (1800 to 0600 hours) cycle. The signals from
the pressure sensor were converted and sent via the radio frequency
transmitter to a telemetry receiver, connected to a BCM-100
consolidation matrix and a Dataquest IV acquisition system (Data
Sciences International). Systolic and diastolic pressure and heart rate
were continuously recorded at 5-min intervals, each reading
representing the average BP during a 10-s sampling period.
In vivo measurement of cardiac function
Left ventricular size and function were assessed by echocardiogra-
phy.31 The tests were performed on WT and KO mice (3 months
old) under light anesthesia with inhaled isoflurane. The echocardio-
graphic data were collected in both short- and long-axis views at
heart rates 4400 b.p.m. A total of 5 measurements were made in
each view (total 10 measurements) and averaged together to obtain
functional and anatomical data. All imaging was performed
using the Vevo770 system (VisualSonics, Toronto, Canada) with a
40mHz probe.
Plasma aldosterone
Plasma aldosterone concentrations were determined using the DSL-
8600 ACTIVE Aldosterone Coated-Tube Radioimmunoassay Kit
according to the manufacturer’s instructions (Diagnostic Systems
Laboratories, Webster, TX).
Plasma catecholamine measurements
Catecholamines were assayed in plasma by high-pressure liquid
chromatography with electrochemical detection, as previously
described.32 The lower limit of detection for dopamine, NE, and
epinephrine ranged from 350 to 1000 fmol.
Synthesis of recombinant renalase protein
Recombinant renalase (37E isoform) was synthesized as previously
described.11 Briefly, the renalase coding region was amplified by
PCR and cloned into the pGEX-4T (Promega, Madison, WI) in
frame with a glutathione S-transferase tag (26 kDa) at the N-
terminus. Escherichia coli BL21 were transformed and grown at
37 1C for 16 h with 0.1 mM FAD. Isopropyl b-D-1-thiogalactopyrano-
side (0.5mmol/l) was added for the last 3.5 h of culture. The
renalase fusion protein was purified using Glutathione Sepharose.
Untagged recombinant renalase was also synthesized in E. coli,
purified, and refolded.
Cardiac ischemia/reperfusion
Isolated perfused hearts were examined by the Langendorff method
using a Radnoti isolated perfused heart System (model 120103EZ,
Monrovia, CA).33 Hearts were excised from adult mice (renalase KO
and WT littermates) that had been anesthetized, weighed, and
heparinized (500U/100 g body weight), and immediately placed in
ice-cold buffer solution. The aorta was cannulated on a 20-gauge Luer
stub adapter (Warner Instruments, Hamden, CT) with a stainless steel
shaft and perfused with physiological buffer, at a flow rate of 1.5ml/
min. An incision was made at the root of the pulmonary artery to
drain coronary effluent. A constant-flow pump provided coronary
perfusion at a rate of B2ml/min through the aorta. The coronary
perfusate consisted of (in mmol/l) 118 NaCl, 4.7 KCl, 1.2 KH2PO4,
1.5 CaCl2, 1.2 MgCl2, 23 NaHCO3, 10.0 dextrose, and 0.3 EDTA,
gassed with 95% O2/5% CO2 and adjusted to pH of 7.4. The hearts
were then subjected to no-flow global ischemia for 15min, and then
reperfused for 90min. Left ventricular function was measured using a
fluid-filled latex balloon containing a catheter-tip transducer (model
SPR-671; Millar, Houston, TX) inserted into the left ventricle. The
distal end of the balloon system was connected via pressure
transducer to PowerLab ADInstruments, and intraventricular pres-
sure was digitally recorded. Infarction size was assessed using
triphenyltetrazolium staining. At the end of the experimental
procedure, a 10% (wt/vol) solution of triphenyltetrazolium chloride
in phosphate buffer was infused into the coronary vasculature
through a side arm of the aortic cannula. Once the heart had been
discolored (triphenyltetrazolium stains viable myocardium deep red),
the heart was perfused with 4% formalin. The heart was sectioned
into 1mm thick slices, which were illuminated and photographed.
Myocardial infarct size was assessed by computer-assisted planimetry
(ImageJ 1.34s) of triphenyltetrazolium-stained sections.
Nitrate and nitrite measurements
Plasma and tissue nitrate and nitrite were measured using the
Nitrate/Nitrite calorimetric assay kit, and according to the
manufacturer’s instructions (Cayman Chemical Company, Ann
Harbor, MI).
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Glutathione levels
Reduced glutathione and oxidized glutathione were measured in
plasma and tissue using the Glutathione Assay Kit, and according to
the manufacturer’s instructions (BioVision Research Products,
Mountain View, CA).
NAD and NADH measurements
Tissue NADþ and NADH concentrations in KO and WTmice were
determined by calorimetry using the EnzyChrom NADþ /NADH
assay kit, and according to the manufacturer’s protocol (Bioassay
Systems, Hayward, CA).
NADH oxidase activity
The assay buffer contained 50mmol/l potassium phosphate, pH 7.5,
and 1mmol/l EDTA. NADH was made fresh and added to a final
concentration ranging from 50 to 1000mM. The reactions were
initiated by adding plasma (40ml) or recombinant renalase (6–30mg)
to 200ml/ml of assay buffer in 96-well plate cuvettes (0.6-cm path
length). Absorbance at 340 nM was measured in a plate reader at 25 or
37 1C, and recorded every 4min for 60min. The amount of NADH
oxidized to NAD was calculated from the decrease in absorbance at
340 nM using a molar extinction coefficient of 0.00622mmol/cm at
340 nm. To estimate kinetic parameters (Km and Vmax), initial
velocity was plotted against substrate concentration, and the data
were fitted to the Michaelis–Menten equation using nonlinear
regression (GraphPad Prism, GraphPad Software, La Jolla, CA).
Western blot analysis
Studies were carried out as previously described using a polyclonal
anti-renalase antibody.11
Statistical analysis
Standard unpaired Student’s t-tests were used for group compar-
isons at equivalent periods. All data are means±s.e., and Po0.05
was accepted as a statistically significant difference.
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